Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

306 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
Radiotherapy research priorities for the UK.
Maughan TS, Illidge TM, Hoskin P, McKenna WG, Brunner TB, Stratford IJ, Harrington KJ, Plummer R, Billingham LJ, Nutting C, Burnet NG, Mackay RI, Oliver A, Young C, Chan CS; NCRI Clinical and Translational Radiotherapy Research Working Group. Maughan TS, et al. Among authors: stratford ij. Clin Oncol (R Coll Radiol). 2010 Oct;22(8):707-9. doi: 10.1016/j.clon.2010.03.006. Epub 2010 Apr 2. Clin Oncol (R Coll Radiol). 2010. PMID: 20363111 No abstract available.
Guidelines for preclinical and early phase clinical assessment of novel radiosensitisers.
Harrington KJ, Billingham LJ, Brunner TB, Burnet NG, Chan CS, Hoskin P, Mackay RI, Maughan TS, Macdougall J, McKenna WG, Nutting CM, Oliver A, Plummer R, Stratford IJ, Illidge T. Harrington KJ, et al. Among authors: stratford ij. Br J Cancer. 2011 Aug 23;105(5):628-39. doi: 10.1038/bjc.2011.240. Epub 2011 Jul 19. Br J Cancer. 2011. PMID: 21772330 Free PMC article. Review. No abstract available.
Clinical development of new drug-radiotherapy combinations.
Sharma RA, Plummer R, Stock JK, Greenhalgh TA, Ataman O, Kelly S, Clay R, Adams RA, Baird RD, Billingham L, Brown SR, Buckland S, Bulbeck H, Chalmers AJ, Clack G, Cranston AN, Damstrup L, Ferraldeschi R, Forster MD, Golec J, Hagan RM, Hall E, Hanauske AR, Harrington KJ, Haswell T, Hawkins MA, Illidge T, Jones H, Kennedy AS, McDonald F, Melcher T, O'Connor JP, Pollard JR, Saunders MP, Sebag-Montefiore D, Smitt M, Staffurth J, Stratford IJ, Wedge SR; NCRI CTRad Academia-Pharma Joint Working Group. Sharma RA, et al. Among authors: stratford ij. Nat Rev Clin Oncol. 2016 Oct;13(10):627-42. doi: 10.1038/nrclinonc.2016.79. Epub 2016 Jun 1. Nat Rev Clin Oncol. 2016. PMID: 27245279 Free article.
A novel systemically administered Toll-like receptor 7 agonist potentiates the effect of ionizing radiation in murine solid tumor models.
Adlard AL, Dovedi SJ, Telfer BA, Koga-Yamakawa E, Pollard C, Honeychurch J, Illidge TM, Murata M, Robinson DT, Jewsbury PJ, Wilkinson RW, Stratford IJ. Adlard AL, et al. Among authors: stratford ij. Int J Cancer. 2014 Aug 15;135(4):820-9. doi: 10.1002/ijc.28711. Epub 2014 Jan 17. Int J Cancer. 2014. PMID: 24390981 Free PMC article.
Intravenous administration of the selective toll-like receptor 7 agonist DSR-29133 leads to anti-tumor efficacy in murine solid tumor models which can be potentiated by combination with fractionated radiotherapy.
Dovedi SJ, Adlard AL, Ota Y, Murata M, Sugaru E, Koga-Yamakawa E, Eguchi K, Hirose Y, Yamamoto S, Umehara H, Honeychurch J, Cheadle EJ, Hughes G, Jewsbury PJ, Wilkinson RW, Stratford IJ, Illidge TM. Dovedi SJ, et al. Among authors: stratford ij. Oncotarget. 2016 Mar 29;7(13):17035-46. doi: 10.18632/oncotarget.7928. Oncotarget. 2016. PMID: 26959743 Free PMC article.
306 results